Crossmark

Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022

Crossref DOI link: https://doi.org/10.1007/s12247-022-09692-4

Published Online: 2022-11-16

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dmour, Isra https://orcid.org/0000-0001-8926-2477
License Information

Text and Data Mining valid from 2022-11-16

Version of Record valid from 2022-11-16
More Information

Article History

Accepted: 16 October 2022

First Online: 16 November 2022

Declarations

:

: No human subjects were involved in this study. IRB/REC review not required.

: The author declares no conflict of interest.

Document is current

Any future updates will be listed below